期刊文献+

HPV 16L1基因的原核表达及表达条件的优化 被引量:3

Prokaryotic expression of HPV 16L1 and optimization of expression conditions
下载PDF
导出
摘要 目的:构建HPV16L1基因的原核表达质粒,并优化其表达条件。方法:根据GeneBank中的HPV序列及pGEX-KG中的多克隆位点设计引物,以含有HPV全长基因片段重组质粒为模板,经PCR扩增出1 500 bp的DNA片段。将所得片段与pGEX-KG载体连接,转化JM109大肠杆菌,筛选阳性克隆。其扩增片段测序结果与原序列一致,表明原核表达载体pGEX-KG-HPV16L1已构建成功。提取pGEX-KG-HPV16L1质粒转化到BL21(DE3)表达菌株中,经IPTG诱导后收集菌体,进行SDS-PAGE,Western Blot鉴定。结果:在大肠杆菌中获得HPV16L1基因融合表达,融合蛋白的相对分子量为83kDa;表达的蛋白能与抗HPV16L1抗体发生特异性反应。结论:HPV16L1基因在大肠杆菌中获得高效表达,为HPV16L1疫苗的研制奠定了基础。 Objective: To construct the HPV16 L1 prokaryotic expression plasmid and to optimize its expression.Methods: A pair of primers was designed according to plasmid sequences of pGEX-KG and the HPV16L1 genes published by GeneBank.The DNA fragment of 1 500 bp was amplified by PCR from the HPV recombinant plasmid with HPV16L1 gene,then cloned into pGEX-KG and transformed into the host E.coli strain JM109.The pGEX-KG-HPV16L1 plasmid was taken and transformed into BL21(DE3) for expression.Induced by IPTG at 37℃,the expression product of HPV16L1 gene was identified by SDS-PAGE and Western blot.Results: HPV16L1 fusion protein was expressed successfully in the form of inclusion bodies.The molecular weight was 83 kD.Meanwhile,the optimum condition of HPV16L1 fusion protein expression was induced with 1.0 mmol·L-1 IPTG for 4 h.The fusion protein reacted specifically with antibodies against HPV16L1.Conclusion: The prokaryotic expression vector of HPV16L1 gene has been constructed and expressed in E.coli successfully.
出处 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2010年第4期395-398,418,共5页 Journal of Zhejiang University(Medical Sciences)
基金 国家自然科学基金资助项目(30571714 60873103) 国家自然科学基金重点项目(30830090) 重庆市科委自然基金(2008BB5331 2009BB7231) 重庆市教委科学技术研究项目(KJ090614) 教育部科学技术研究重点项目(210178)资助
关键词 病毒蛋白质类/生物合成 病毒蛋白质类/遗传学 大肠杆菌/遗传学 基因表达 克隆 分子 乳头状瘤病毒 人/遗传学 HPV16L1 原核表达 GST融合蛋白 疫苗 Viral proteins/biosyn Viral proteins/genet Escherichia coli/genet Gene expression Cloning molecular Papillomavirus human/genet HPV 16L1 Prokaryotic expression GST fusion protein Vaccines
  • 相关文献

参考文献9

  • 1YAN Y D,SAUL S.Interaction of zyxin,a focal adhesion protein,with the E6 protein from human papillomavirus type 6 results in its nuclear translocation[J].J Virol,2001,75:11791-11802.
  • 2MARC J S,NATHALIE G,JOHN H.Multiple signaling pathways leading to the activation of interferon regulatory factor 3[J].Biochem Pharmacol,2002,64(5-6):985-992.
  • 3LEHTINEN M,APTER D,DUBIN G,et al.Enrolment of 22000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy:guarding against guessing[J].Int J STD AIDS,2006,17 (8):517-521.
  • 4JANSEN K U,SHAW A R.Human papillomavirus vaccines and prevention of cervical cancer[J].Annu Rev Med,2004,55:319-331.
  • 5CHEN X S,GASNI G,HARRISON S C,et al.Papillomavirus capsid protein expression in Escherichia coli:purification and assembly of HPV11 and HPV16 L1[J].J Mol Biol,2001,307(1):173-182.
  • 6FANG N X,FRAZER I H,FERNANDO G J.Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system[J].Biotechnol Appl Biochem,2000,32(Pt 1):27-33.
  • 7KUMAR A,ZHAO Y,MENG G,et al.Human papillomavirus oncoprotein 16L1 inactivates the transcriptional coactivator human ADA3[J].Mol Cell Biol,2005,22(16):5801-5812.
  • 8KUKIMOTO I,AIHARA S,YOSHIIKE K,et al.Human papillomavirus oncoprotein 16L1 binds to the C-terminal region of human minichromosome maintenance 7 protein.Biochem[J].Biophys Res Commun,1998,249:258-262.
  • 9SERVANT M J,TEN OEVER B,LEPAGE C,et al.Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3[J].J Biol Chem,2001,276(1):355-363.

同被引文献27

  • 1郝东风,马正海,王艳萍,热西旦,张富春.HPV16 L1基因的原核表达及免疫反应性鉴定[J].细胞与分子免疫学杂志,2005,21(4):428-431. 被引量:3
  • 2韦琴,彭贵青,金梅林,朱裕东,周红波,郭红燕,陈焕春.鸡α干扰素基因的克隆、原核表达及抗病毒效果研究[J].生物工程学报,2006,22(5):737-743. 被引量:17
  • 3Tota JE,Chevarie-Davis M,Richardson LA. Epidemiology and burden of HPV infection and related diseases:implications for prevention strategies[J].{H}Preventive Medicine,2011,(Suppl 1):S12-S21.
  • 4Schiffman M,Castle PE,Jeronimo J. Human papillomavirus and cervical cancer[J].{H}LANCET,2007,(9590):890-907.
  • 5Yue Y,Yang H,Wu K. Genetic Variability in L1 and L2 genes of HPV-16 and HPV-58 in Southwest China[J].PloS one,2013,(01):e55204.
  • 6Villa LL,Costa RL,Petta CA. Prophylactic quadrivalent human papillomavirus(types 6,11,16,and 18)L1 virus-like particle vaccine in young women:a randomised double-blind placebo-controlled multicentre phase II efficacy trial[J].{H}LANCET ONCOLOGY,2005,(05):271-278.
  • 7Szarewski A. HPV vaccine:Cervarix[J].{H}Expert Opinion on Biological Therapy,2010,(03):477-487.
  • 8谷鸿喜;钟照华;凌虹.中国妇女宫颈癌组织中 HPV16L1 基因的克隆与测序[J]{H}中华微生物学和免疫学杂志,1998(02):95.
  • 9Zhang W,Carmichael J,Ferguson J. Expression of human papillomavirus type 16 L1 protein in Escherichia coli:denaturation,renaturation,and self-assembly of virus-like particles in vitro[J].{H}VIROLOGY,1998,(02):423-431.
  • 10Kim HJ,Lee SJ,Kim HJ. Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in Saccharomyces cerevisiae[J].{H}Journal of Biotechnology,2010,(01):31-36.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部